Results 41 to 50 of about 34,440,044 (184)

Glucagon-Like Peptide-1 Agonists to Manage Weight Gain in Patients Taking Antipsychotics [poster] [PDF]

Patients struggling with schizophrenia have significant weight gain and lower life expectancy than the general population. These differences may be the result of commonly prescribed antipsychotic medications.
Nash, Samuel
core   +1 more source

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes

Сахарный диабет, 2018
Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications.
Nina A. Petunina, Milena Е. Telnova
doaj   +1 more source

Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes

Journal of Diabetes Investigation
Aims To evaluate characteristics and glycemic outcomes in individuals with type 2 diabetes using injectable therapies in real‐world clinical practice in Tianjin, China.
Qiumei Zhang, Yaqing Fan, Xixi Liu, Minlu Zhang, Jiewen Zhang, Qin Du, Lei Kang, Liming Chen   +7 more
doaj   +1 more source

GLP-1 Receptor Agonists in Diabetic Nephropathy: Clinical Evidence, Molecular Mechanisms, and Future Perspectives

Turkish Journal of Nephrology
Diabetic nephropathy (DN) remains the predominant etiology of chronic kidney disease (CKD) worldwide, significantly resulting in mortality and morbidity among individuals with diabetes mellitus.
Gerry George Mathew
doaj   +1 more source

Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations

, 2018
Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesity and diabetes.
Michael Wagner (56165), Stefania Pfeiffer-Marek (2121412), Siegfried Stengelin (4007183), Andreas Evers (1585204), Herman Schreuder (1830412), Martin Lorenz (2248633), Anja Pfenninger (5447939), Dieter Kadereit (2668252), Michael Kurz (1578484), Torsten Haack (2670532), Katrin Lorenz (440267), Anish Konkar (5447936), Martin Bossart (2456944), Ulrike Lukasczyk (5447945), Ralf Elvert (177237), Andreas Herling (5447942)   +15 more
core   +1 more source

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Nature Communications
Glucagon-like peptide-1 receptor agonists act via appetite suppression and caloric restriction. These treatments can result in significant muscle loss, likely due to evolutionary mechanisms protecting against food scarcity as muscle is a major energy ...
Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman   +11 more
doaj   +1 more source

Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection

Frontiers in Medicine
Endothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease.
Allegra Battistoni, Linda Piras, Nicola Tartaglia, Francesco Maria Carrano, Claudia De Vitis, Emanuele Barbato   +5 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis

JAMA Ophthalmology
ImportanceEmerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for glycemic control in diabetes, may possess anti-inflammatory properties. Understanding their potential protective role against uveitis could provide insights into novel therapeutic strategies.ObjectiveTo evaluate whether being prescribed a ...
Mohan, Nitesh, Srivastava, Sunil K., Schulgit, Matthew J., Nowacki, Amy S., Kaelber, David C., Sharma, Sumit   +5 more
openaire   +2 more sources

Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists

Endocrinology Research and Practice, 2022
Glucagon-like peptide-1 is the most potent incretin secreted from the intestinal tract. It is synthesized by L-cells in the jejunum and distal ileum of the gastrointestinal system.
Dilek Tüzün
doaj  

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias

Journal of Arrhythmia
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal, Muhammad Hanif, Aman Goyal, Juveriya Yasmeen, Vamsi Garimella, Yusra Mashkoor, Roopeessh Vempati, Novonil Deb, Yusra Minahil Nasir, Kripa Rajak, Abhigan Babu Shrestha, Jishanth Mattumpuram, Andrew Weinberg   +12 more
doaj   +1 more source